circRIG-I interacts with DDX3X, which in turn stimulates MAVS/TRAF5/TBK1 signaling cascade, eventually activating IRF3-mediated type I IFN transcription and aggravating inflammatory damage.
Mutant RIG-I enhances cancer-related inflammation through activation of circRIG-I signaling.